Cargando…

Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours

BACKGROUND: The aim of this prospective study was to examine whether discontinuation of proton pump inhibitors (PPIs) or replacement by H(2)-receptor antagonists (H2RA) resulted in a decrease of chromogranin A (CgA) levels in 196 patients with well-differentiated neuroendocrine tumours (NETs). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korse, C M, Muller, M, Taal, B G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208502/ https://www.ncbi.nlm.nih.gov/pubmed/21989216 http://dx.doi.org/10.1038/bjc.2011.380

Ejemplares similares

Ten-Fold Elevation of Chromogranin A Level Unrelated to a Neuroendocrine Tumor: A Case Report of the Diagnostic Interference of Proton Pump Inhibitors
por: Alkhayat, Maha J, et al.
Publicado: (2023)

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
por: Baudin, E., et al.
Publicado: (1998)

The elusive role of proton pump inhibitors in COVID-19: Can plasma Chromogranin A levels hold the key?
por: Sciorati, Clara, et al.
Publicado: (2023)

Spectrophotometric Determination of Certain Benzimidazole Proton Pump Inhibitors
por: Syed, A. A., et al.
Publicado: (2008)

A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors
por: Modlin, Irvin M, et al.
Publicado: (2014)

A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours
por: Bernini, G P, et al.
Publicado: (2001)

Association between Parkinson's disease and proton pump inhibitors therapy in older people
por: Lai, Shih-Wei, et al.
Publicado: (2020)

Comparative Study of Proton Pump Inhibitors on Dexamethasone Plus Pylorus Ligation Induced Ulcer Model in Rats
por: Thippeswamy, A. H. M., et al.
Publicado: (2010)

Circadian variations in salivary chromogranin a concentrations during a 24-hour period in dogs
por: Kanai, Kazutaka, et al.
Publicado: (2008)

Malignant Range Elevation of Serum Chromogranin A due to Inadvertent Use of Proton Pump Inhibitor in a Subject with Pancreatic Incidentaloma
por: Malabu, Usman Hammawa, et al.
Publicado: (2011)

Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors
por: Tomita, Tatsuo
Publicado: (2020)

Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes
por: Bödvarsdóttir, T. B., et al.
Publicado: (2010)

A149 CHARACTERIZING INAPPROPRIATE PROTON-PUMP INHIBITOR DISCONTINUATION IN PATIENTS WITH ESOPHAGEAL STRICTURES
por: Kecskemeti, K L, et al.
Publicado: (2023)

A Randomized Open-Label Study of Two Methods of Proton Pump Inhibitors Discontinuation
por: Hendricks, Emily, et al.
Publicado: (2021)

Comparison of PCR-based detection of chromogranin A mRNA with traditional histological lymph node staging of small intestinal neuroendocrine neoplasia
por: Lawrence, Ben, et al.
Publicado: (2012)

Clinical Usefulness of Plasma Chromogranin A in Pancreatic Neuroendocrine Neoplasm
por: Paik, Woo Hyun, et al.
Publicado: (2013)

Cerebrospinal Fluid Levels of Chromogranin A in Parkinson’s Disease and Multiple System Atrophy
por: Kaiserova, Michaela, et al.
Publicado: (2021)

IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells
por: Münzberg, Christin, et al.
Publicado: (2015)

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
por: Medley, L, et al.
Publicado: (2011)

Results of an Intervention in an Academic Internal Medicine Clinic to Continue, Step-Down, or Discontinue Proton Pump Inhibitor Therapy Related to a Tennessee Medicaid Formulary Change
por: Ramser, Kristie L., et al.
Publicado: (2009)

Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors
por: Di Giacinto, Paola, et al.
Publicado: (2018)

Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors
por: Baekdal, Jonas, et al.
Publicado: (2020)

The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Moonjin, et al.
Publicado: (2016)

Proton pump inhibitors display anti‐tumour potential in glioma
por: Li, Bihan, et al.
Publicado: (2022)

Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy
por: Holmberg, Dag, et al.
Publicado: (2022)

Iron deficiency anemia from iron malabsorption caused by proton pump inhibitors
por: Boxer, Michael
Publicado: (2020)

Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors
por: van Adrichem, R C S, et al.
Publicado: (2013)

Commentary to “Chromogranin A: Biological Function and Clinical Utility in Neuroendocrine Tumor Disease”
por: Jeske, Wojciech, et al.
Publicado: (2010)

Chromogranin A and Its Fragments as Regulators of Small Intestinal Neuroendocrine Neoplasm Proliferation
por: Giovinazzo, Francesco, et al.
Publicado: (2013)

Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
por: Gut, Paweł, et al.
Publicado: (2016)

Low accuracy of chromogranin A for diagnosing early-stage pancreatic neuroendocrine tumors
por: Tseng, Chao-Ming, et al.
Publicado: (2018)

Disappearance of Gastric Hyperplastic Polyps after the Discontinuation of Proton Pump Inhibitor in a Patient with Liver Cirrhosis
por: Yasugi, Kengo, et al.
Publicado: (2021)

Proton pump inhibitors and the risk of severe cognitive impairment: The role of posttraumatic stress disorder
por: Clouston, Sean A.P., et al.
Publicado: (2017)

The effects of discontinuing cinacalcet at the time of kidney transplantation
por: Jadoul, Michel, et al.
Publicado: (2010)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
por: Lyons, Yasmin A., et al.
Publicado: (2014)

Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas
por: Qiao, Xin-Wei, et al.
Publicado: (2014)

Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors
por: Hijioka, Masayuki, et al.
Publicado: (2014)

Chromogranin A as a Marker for Diagnosis, Treatment, and Survival in Patients With Gastroenteropancreatic Neuroendocrine Neoplasm
por: Wang, Yu-hong, et al.
Publicado: (2014)

My burning issues in neuroendocrine tumours (NET)
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c1neiuld81lk64o76bqnh2bo8a